Treatment of Inflammatory Bowel Disease with Biologics
31 Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestina ...
32 Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, et al. Maintenance of efficacy and continuing safety of g ...
© Springer International Publishing AG 2018 33 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease wi ...
34 mesalazine, azathioprine, semi-elemental diet, and metronidazole [ 8 ]. After 2 years of CD-related symptoms and stunted grow ...
35 ability to detect subtle differences in dose response. Over 12 weeks, the difference in clinical response for IFX versus plac ...
36 A key concern about IFX is the cost, given both the drug cost and infusion center cost. However numerous studies have evaluat ...
37 for up to 16 weeks. Seventy-three percent of subjects had an improvement in fistula symptoms with 36% in remission [ 27 ]. Ad ...
38 of the entire CHARM cohort (including those who received open-label ADA) found that continuous ADA was a more effective treat ...
39 scored using the CDEIS, and while the initial assessment was study site specific, the final assessment was performed by a bli ...
40 placebo with all ranging between 45% and 60% response (defined as decrease in CDAI ≥ 100). A post hoc analysis of the data re ...
41 primary outcome of clinical remission at week 6 (32% and 25% for CZP and placebo, respectively, p < 0.174) [ 50 ]. However ...
42 Pediatric Efficacy Similar to the adult population, anti-TNFs have been effective in inducing and maintaining remission in pe ...
43 Why Aren’t All TNFs the Same? While anti-TNF medications represent an effective class of therapy for CD, not all anti-TNFs ar ...
44 decreases in hospitalizations and surgeries as well as improving quality of life. It is not known at this time if the anti-TN ...
45 Feagan BG, Kozma CM, Slaton TL, Olson WH, Wan GJ. Healthcare costs for Crohn’s disease patients treated with Infliximab:CD: ...
46 Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical respo ...
47 Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, et al. Certolizumab pegol for active Crohn’s dis ...
48 Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23(5):617–28. Sandborn W ...
© Springer International Publishing AG 2018 49 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease wi ...
50 etanercept is probably less effective than infliximab and adalimumab, although data regarding this comparison are limited. A ...
«
1
2
3
4
5
6
7
8
9
10
»
Free download pdf